Comparative efficacy of treatments for chronic central serous chorioretinopathy: A systematic review with network meta-analyses

Acta Ophthalmol. 2023 Mar;101(2):140-159. doi: 10.1111/aos.15263. Epub 2022 Sep 30.

Abstract

Treatment of chronic central serous chorioretinopathy (cCSC) remains a topic of controversy. As cCSC is a disease that can wax and wane, treatment efficacy is difficult to assess especially when trials compare active treatments without any placebo/control group. In this study, we systematically reviewed short-term efficacies of any cCSC treatment tested in randomized controlled trials (RCT) and employed network meta-analyses to compare to non-treatment controls. We searched 11 literature databases on 20 March 2022 for RCTs of treatment of cCSC. We identified 17 RCTs including a total of 1172 eyes. Treatments included conventional laser (44 eyes), half-dose or half-fluence photodynamic therapy (PDT) (298 eyes), ranibizumab (16 eyes), antioxidants (50 eyes), mineralocorticoid receptor antagonists (187 eyes), rifampicin (91 eyes), selective retina therapy (SRT) (67 eyes) and subthreshold micropulse laser (192 eyes). Compared with controls, significant benefit on complete subretinal fluid resolution was only obtained from half-dose or half-fluence PDT (OR: 20.6; 95% CI: 6.3-66.7; p < 0.0001) and conventional laser (OR: 36.4; 95% CI: 2.0-655.7; p = 0.015), and at an order of magnitude lower degree from SRT (OR: 3.4; 95% CI: 1.7-6.8; p = 0.00075). Compared with controls and after sensitivity analyses, significant benefit in the change in best-corrected visual acuity was only obtained by half-dose/-fluence PDT (-0.13 logMAR; 95% CI: -0.20 to -0.06 logMAR; p = 0.00021). In conclusion, three treatment options provide significant improvement over no treatment: half-dose/-fluence PDT, conventional laser and to a much lesser degree SRT. Considering that conventional laser can only be applied for extrafoveal leaks, and the long-term data available for PDT-based treatments finding persisting treatment results, half-dose or half-fluence PDT is the only viable treatment option for patients with cCSC. Shortage issues with verteporfin should not lead to employment of ineffective treatment modalities, as they put patients at unnecessary risk of adverse events.

Keywords: central serous chorioretinopathy; network meta-analysis; subretinal fluid; systematic review; treatment comparison.

Publication types

  • Meta-Analysis
  • Systematic Review
  • Review

MeSH terms

  • Central Serous Chorioretinopathy* / diagnosis
  • Central Serous Chorioretinopathy* / drug therapy
  • Chronic Disease
  • Fluorescein Angiography
  • Humans
  • Network Meta-Analysis
  • Photochemotherapy* / methods
  • Photosensitizing Agents / therapeutic use
  • Porphyrins* / therapeutic use
  • Randomized Controlled Trials as Topic
  • Tomography, Optical Coherence
  • Treatment Outcome
  • Visual Acuity

Substances

  • Photosensitizing Agents
  • Porphyrins